We are live on ! Find out more
AGRX

Agile Therapeutics
AGRX

Delisted

AGRX was delisted on the 25th of March, 2024.

Back to rankings

62 hedge funds and large institutions have $133M invested in Agile Therapeutics in 2016 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 16 increasing their positions, 11 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,100% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 1

45% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 11

22% more funds holding

Funds holding: 51 → 62 (+11)

20% less capital invested

Capital invested by funds: $167M → $133M (-$33.8M)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
62
Holders Change
+11
Holders Change %
+21.57%
% of All Funds
1.55%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.07%
New
12
Increased
16
Reduced
11
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CC
Caxton Corporation
New Jersey
+$2.45M
2
EAM
EverPoint Asset Management
Connecticut
+$1.4M
3
DM
Deerfield Management
New York
+$1.04M
4
PVI
Pura Vida Investments
New York
+$981K
5
HCMT
Highland Capital Management (Texas)
Texas
+$827K

Top Sellers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
-$3.55M
2
AC
Aisling Capital
New York
-$3.31M
3
PA
Perceptive Advisors
New York
-$2.51M
4
GIM
Granahan Investment Management
Massachusetts
-$1.91M
5
JGC
J. Goldman & Co
New York
-$1.04M
Name Holding Trade Value Shares
Change 		Change in
Stake
Deutsche Bank
51
Deutsche Bank
Germany
$41K +$42K +3 +300%
Royal Bank of Canada
52
Royal Bank of Canada
Ontario, Canada
$28K – – –
BA
53
BlackRock Advisors
Delaware
$27K – – –
Wells Fargo
54
Wells Fargo
California
$26K – – –
Citigroup
55
Citigroup
New York
$20K +$28K +2 New
Manulife (Manufacturers Life Insurance)
56
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$19K +$28K +2 New
Legal & General Group
57
Legal & General Group
United Kingdom
$17K +$28K +2 New
UBS Group
58
UBS Group
Switzerland
$17K +$28K +2 New
CSS
59
Cubist Systematic Strategies
Connecticut
$15K +$14K +1 New
Bank of America
60
Bank of America
North Carolina
$10K +$14K +1 New
IA
61
IFP Advisors
Florida
$10K +$14K +1 New
TRCT
62
Tower Research Capital (TRC)
New York
$8K +$14K +1 New
MAM
63
Meeder Asset Management
Ohio
$5K – – –
Barclays
64
Barclays
United Kingdom
$3K – – –
BlackRock
65
BlackRock
New York
$3K – – –
BNP Paribas Financial Markets
66
BNP Paribas Financial Markets
France
$314 – – –
BFM
67
Boothbay Fund Management
New York
– -$103K -7 Closed
1 2
3

AGRX Hedge Fund Activity: Q4 2016 in Review

62 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q4 2016, worth a combined $133M — down 20% from $167M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new AGRX positions and 1 closed out — a net gain of 11 holders — while 16 added to existing stakes and 11 trimmed.

The largest buyer was Caxton Corporation, adding an estimated $2.45M. The largest seller was Vivo Capital, cutting an estimated $3.55M.

  • 62 institutional investors held Agile Therapeutics (AGRX) as of Q4 2016, up from 51 in Q3 2016.
  • Funds reported $133M of Agile Therapeutics stock for Q4 2016, down 20% quarter-over-quarter.
  • 12 funds opened new Agile Therapeutics positions in Q4 2016 and 1 closed out, a net change of +11 holders.
  • The largest Agile Therapeutics buyer in Q4 2016 was Caxton Corporation, an estimated $2.45M added.
  • The largest Agile Therapeutics seller in Q4 2016 was Vivo Capital, an estimated $3.55M sold.

Based on aggregated 13F filings for Q4 2016.